Paraneoplastik Gastrointestinal Sendromlar
Özet
Paraneoplastik gastrointestinal sendromlar (PNS), bir tümör veya metastazın doğrudan kitle etkisine bağlı olmaksızın, uzak organlarda fonksiyon bozukluğuna yol açan nadir sistemik tablolardır. Neoplastik hücrelerden salınan hormonlar, büyüme faktörleri, sitokinler ve konakçının otoimmün yanıtıyla gelişen bu sendromların klinik teşhisi oldukça zordur. Malignite ilişkili dismotilite; özofagus (psödoakalazya), mide (gastroparezi) ve bağırsakları (intestinal psödo-obstrüksiyon) etkileyebilir. Özellikle küçük hücreli akciğer, meme, over kanseri ve lenfoma gibi malignitelerde ANNA-1 (anti-Hu) ve PCA-1 gibi spesifik otoantikorlar salgılanarak Cajal hücrelerinde hasara yol açar. Hastalarda disfaji, kusma, dirençli bulantı, karın ağrısı ve ciddi kilo kaybı gelişir. Tanıda baryumlu grafiler, sintigrafi ve BT gibi görüntülemelerle mekanik tıkanıklıkların dışlanması esastır. Tedavinin temel amacı altta yatan primer tümörün ortadan kaldırılmasıdır. Bunun mümkün olmadığı palyatif durumlarda ise hastanın semptom şiddetine göre (Grad 1-4) beslenme modifikasyonları, prokinetik (metoklopramid, eritromisin) ve antiemetik ajanlar kullanılır. İleri evre refrakter olgularda PEG-J ile dekompresyon, enteral/parenteral beslenme ve immünoterapiler (rituksimab) devreye girer.
Paraneoplastic gastrointestinal syndromes (PNS) are rare systemic disorders causing dysfunction in distant organs, independent of the direct mass effect of a primary tumor or its metastases. Triggered by tumor-secreted hormones, cytokines, growth factors, and the host's immune response, these syndromes present diverse clinical features that complicate diagnosis. Malignancy-associated dysmotility can affect the esophagus (pseudoachalasia), stomach (gastroparesis), and intestines (intestinal pseudo-obstruction). In malignancies like small-cell lung, breast, and ovarian cancers, circulating autoantibodies such as ANNA-1 (anti-Hu) and PCA-1 induce immune-mediated destruction of the interstitial cells of Cajal. Patients experience severe symptoms, including dysphagia, intractable nausea, vomiting, abdominal pain, and weight loss. Diagnostic approaches require ruling out mechanical obstructions via barium swallow tests, gastric emptying scintigraphy, and CT imaging. The primary therapeutic strategy is treating the underlying malignancy. When eradication is impossible, management focuses on symptom severity (Grades 1-4), utilizing dietary modifications, prokinetics (metoclopramide, erythromycin), and antiemetics. Advanced refractory cases mandate invasive interventions like PEG-J decompression, enteral or parenteral nutrition support, and immunotherapies such as rituximab.
Referanslar
Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010;85(9):838- 54
Lee HR, Lennon VA, Camilleri M et al. Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol 2001; 96:373.
Kanaji N, Watanabe N, Kita N, et al. Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol. 2014;5(3):197-223.
Campos CT, Ellis FH Jr, LoCicero J 3rd. Pseudoachalasia: a report of two cases with comments on possible causes and diagnosis. Dis Esophagus. 1997 Jul;10(3):220-4.
Nguyen-tat M, Pohl J, Günter E, et al. Severe paraneoplastic gastroparesis associated with anti-Hu antibodies preceding the manifestation of small-cell lung cancer. Z Gastroenterol 2008; 46:274.
Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998; 50:652.
Vernino S, Low PA, Fealey RD, et al. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000; 343:847.
Pardi DS, Miller SM, Miller DL, et al. Paraneoplastic dysmotility: loss of interstitial cells of Cajal. Am J Gastroenterol 2002; 97:1828-33.
Kahrilas PJ, Kishk SM, Helm JF, et al. Comparison of psedoachalasia and achalasia. Am J med 1987;82:439-46
Hoogerwerf WA, Pasricha PJ, Kalloo AN, Schuster MM. Pain: the overlooked symptom in gastroparesis. Am J Gastroenterol 1999; 94:1029.
Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol 2008; 103:753.
Kuo B, Maneerattanaporn M, Lee AA, et al. Generalized transit delay on wireless motility capsule testing in patients with clinical suspicion of gastroparesis, small intestinal dysmotility, or slow transit constipation. Dig Dis Sci 2011; 56:2928.
Bruera E, Seifert L, Watanabe S, et al. Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage 1996; 11:147.
Desautels SG, Hutson WR, Christian PE, et al. Gastric emptying response to variable oral erythromycin dosing in diabetic gastroparesis. Dig Dis Sci 1995; 40:141.
Banh HL, MacLean C, Topp T et al. The use of tegaserod in critically ill patients with impaired gastric motility. Clin Pharmacol Ther 2005; 77:583.
Camilleri M, Balm RK, Zinsmeister AR. Determinants of response to a prokinetic agent in neuropathic chronic intestinal motility disorder. Gastroenterology 1994; 106:916.
Silvers D, Kipnes M, Broadstone V, et al. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther 1998; 20:438.
Kim SW, Shin IS, Kim JM, et al. Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment. Psychosomatics 2006; 47:440.
Fahler J, Wall GC, Leman BI. Gastroparesis-associated refractory nausea treated with aprepitant. Ann Pharmacother 2012; 46:e38.
Lacy BE, Tack J, Gyawali CP. AGA Clinical Practice Update on Management of Medically Refractory Gastroparesis: Expert Review. Clin Gastroenterol Hepatol 2022; 20:491.)
De Giorgio R, Sarnelli G, Corinaldesi R et al. Advances in our understanding of the pathology of chronic intestinal pseudo-obstruction. Gut 2004; 53:1549.
Stanghellini V, Cogliandro RF, De Giorgio R, et al. Natural history of chronic idiopathic intestinal pseudo-obstruction in adults: a single center study. Clin Gastroenterol Hepatol 2005; 3:449.
Kidher ES, Briceno N, Taghi A et al. An interesting collection of paraneoplastic syndromes in a patient with a malignant thymoma. BMJ Case Rep 2012; 2012.
Cerra-Franco JA, Fernandez-Cruz C, Estremera-Marcial R, et al. Anti-Hu-Mediated Paraneoplastic Chronic Intestinal Pseudo-Obstruction Arising From Small Cell Prostate Cancer. ACG Case Rep J 2019; 6:e00105.
Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993; 341:21.
De Giorgio R, Cogliandro RF, Barbara G, et al. Chronic intestinal pseudo-obstruction: clinical features, diagnosis, and therapy. Gastroenterol Clin North Am 2011; 40:787.
Khoshini R, Dai SC, Lezcano S et al. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 2008; 53:1443.
Fuyuki A, Ohkubo H, Higurashi T, et al. Clinical importance of cine-MRI assessment of small bowel motility in patients with chronic intestinal pseudo-obstruction: a retrospective study of 33 patients. J Gastroenterol 2017; 52:577.
Maurer AH, Krevsky B. Whole-gut transit scintigraphy in the evaluation of small-bowel and colon transit disorders. Semin Nucl Med 1995; 25:326.
Lauro A, Zanfi C, Pellegrini S, et al. Isolated intestinal transplant for chronic intestinal pseudo-obstruction in adults: long-term outcome. Transplant Proc 2013; 45:3351.
Badari A, Farolino D, Nasser E, et al. A novel approach to paraneoplastic intestinal pseudo-obstruction. Support Care Cancer 2012; 20:425.
Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001; 120:354.
O'Dea CJ, Brookes JH, Wattchow DA. The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine. Colorectal Dis 2010; 12:540.
Sabbagh C, Amiot A, Maggiori L, et al. Non-transplantation surgical approach for chronic intestinal pseudo-obstruction: analysis of 63 adult consecutive cases. Neurogastroenterol Motil 2013; 25:e680.
Ohkubo H, Fuyuki A, Arimoto J, et al. Efficacy of percutaneous endoscopic gastro-jejunostomy (PEG-J) decompression therapy for patients with chronic intestinal pseudo-obstruction (CIPO). Neurogastroenterol Motil 2017; 29.
Lauro A, Zanfi C, Pellegrini S, et al. Isolated intestinal transplant for chronic intestinal pseudo-obstruction in adults: long-term outcome. Transplant Proc 2013; 45:3351.
Zemrani B, Lambe C, Goulet O. Cannabinoids Improve Gastrointestinal Symptoms in a Parenteral Nutrition-Dependent Patient With Chronic Intestinal Pseudo-Obstruction. JPEN J Parenter Enteral Nutr 2021; 45:427.
